Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04070040 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Camrelizumab for Patients with Recurrent Primary Central Nervous System Lymphoma (PCNSL)

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated October 15, 2024 (before its estimated December 31, 2024 completion). Its status may not reflect the trial's current state.

Record History

  1. Primary completion date: Dec 31, 2023 to Dec 31, 2024v7
  2. Primary completion date: Dec 31, 2022 to Dec 31, 2023
    • Study completion date: Dec 31, 2022 to Dec 31, 2024
    v6
  3. Primary completion date: Sep 1, 2021 to Dec 31, 2022
    • Study completion date: Sep 1, 2022 to Dec 31, 2022
    v5
  4. Start date changed from estimate of Mar 15, 2020 to Feb 13, 2020v4
  5. Start date: Jan 15, 2020 to Mar 15, 2020v3
  6. Trial status: Not Yet Recruiting to Recruiting
    • Start date: Sep 1, 2019 to Jan 15, 2020
    v2
  7. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study is intend to improve the objective response rate in treatment of camrelizumab in recurrent primary central nervous system lymphoma patients.
Trial Details
NCT Number NCT04070040
Lead Sponsor Beijing Sanbo Brain Hospital
Conditions
(from sponsor)		 Primary Central Nervous System Lymphoma
Enrollment 21 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov